{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107276","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.448577+00:00","generated_at":"2026-05-15T11:55:15.628593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling","bullets":["Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).","R&D expenses $16.7M (up $4.8M); net loss $21.2M vs $14.9M in FY2024.","COYA 302 ALSTARS Phase 2 trial actively enrolling across ~25 sites in US and Canada.","FDA accepted IND for COYA 302 in frontotemporal dementia (FTD); Phase 2a expected 2H2026.","Completed $23M public offering and $11.1M private placement; cash runway into 2H2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107276","json":"https://secwatch.observer/filing/0001193125-26-107276.json","markdown":"https://secwatch.observer/filing/0001193125-26-107276.md","text":"https://secwatch.observer/filing/0001193125-26-107276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/0001193125-26-107276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/coya-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:55:15.628593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bfe6dbb7446fddff2110ec31555c01281db3151","claim":"Coya Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $21.2 million.","evidence_excerpt":"Net loss was $21.2 million for the year ended December 31, 2025, compared to net loss of $14.9 million for the year ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/0001193125-26-107276-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$21.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}